放疗联合复方苦参注射液治疗乳腺癌的临床疗效
|
摘要
目的:观察术后放疗联合复方苦参注射液治疗乳腺癌的临床疗效及对患者细胞免疫功能的影响。方法:选取2015年5月—2017年5月我院收治的110例乳腺癌患者为研究对象,按照随机数字表法分为两组,各55例,对照组给予术后放疗治疗,联合组在对照组基础上联合复方苦参注射液(20 mL+250 mL 0.9%氯化钠注射液静脉滴注,qd)治疗。比较两组治疗效果、细胞免疫功能及生存质量改善情况。结果:联合组完全缓解(CR)、客观缓解(RR)率均显著高于对照组,差异有统计学意义(P <0.05);治疗后联合组CD3~+、CD4~+、CD4~+/CD8~+及自然杀伤(NK)细胞水平显著高于治疗前,且高于对照组,CD8~+值较治疗前明显下降,且低于对照组,差异有统计学意义(P <0.05);联合组生存质量总改善率高于对照组,差异有统计学意义(P <0.05)。结论:放疗联合复方苦参注射液治疗乳腺癌的疗效显著,可改善患者的细胞免疫功能,提高生活质量,值得临床推广应用。
Objective: To observe the clinical efficacy of postoperative radiotherapy combined with compound kushen injection in the treatment of breast cancer and its effect on cellular immune functions. Methods:110 patients with breast cancer admitted to our hospital from May 2015 to May 2017 were selected as subjects investigated and divided into two groups according to the random number table method, 55 cases each. The patients in the control group received postoperative radiotherapy, and the patients in the combined group were treated with compound kushen injection(20 mL + 250 mL 0.9% sodium chloride injection, intravenous drip, qd) on the basis of the control group. The therapeutic effect, cellular immune functions and the improvement of quality of life were compared between the two groups. Results: The rates of complete remission(CR) and objective remission(RR) in the combined group were significantly higher than those in the control group, and the differences were statistically significant(P<0.05). The levels of CD3~+, CD4~+, CD4~+/CD8~+ and natural killer(NK) cells in the combined group after treatment were significantly higher than those before treatment, and higher than those in the control group, while the value of CD8~+ was significantly lower than that before treatment, and lower than that in the control group, with statistically significant differences(P<0.05). The overall improvement rate of quality of life in the combined group was higher than that in the control group, and the difference was statistically significant(P<0.05). Conclusion:Radiotherapy combined with compound kushen injection has a significant therapeutic effect on breast cancer, which can improve the patient's cellular immune functions and improve their quality of life, and is worthy of clinical application.
Objective: To observe the clinical efficacy of postoperative radiotherapy combined with compound kushen injection in the treatment of breast cancer and its effect on cellular immune functions. Methods:110 patients with breast cancer admitted to our hospital from May 2015 to May 2017 were selected as subjects investigated and divided into two groups according to the random number table method, 55 cases each. The patients in the control group received postoperative radiotherapy, and the patients in the combined group were treated with compound kushen injection(20 mL + 250 mL 0.9% sodium chloride injection, intravenous drip, qd) on the basis of the control group. The therapeutic effect, cellular immune functions and the improvement of quality of life were compared between the two groups. Results: The rates of complete remission(CR) and objective remission(RR) in the combined group were significantly higher than those in the control group, and the differences were statistically significant(P<0.05). The levels of CD3~+, CD4~+, CD4~+/CD8~+ and natural killer(NK) cells in the combined group after treatment were significantly higher than those before treatment, and higher than those in the control group, while the value of CD8~+ was significantly lower than that before treatment, and lower than that in the control group, with statistically significant differences(P<0.05). The overall improvement rate of quality of life in the combined group was higher than that in the control group, and the difference was statistically significant(P<0.05). Conclusion:Radiotherapy combined with compound kushen injection has a significant therapeutic effect on breast cancer, which can improve the patient's cellular immune functions and improve their quality of life, and is worthy of clinical application.
引文
[1]许贺娟.苦参注射液联合化疗治疗乳腺癌术后患者的临床观察[J].中医临床研究,2017,9(8):120-121.
[2]李立业.复方苦参注射液联合紫杉醇加阿霉素治疗中晚期乳腺癌临床观察[J].新中医,2016,48(1):158-159.
[3]郭太伟,孙宝刚.复方苦参注射液联合雷替曲塞和奥沙利铂治疗晚期结肠癌的价值探讨[J].中国医药指南,2017,15(30):212-213.
[4]陈晟.晚期非小细胞肺癌应用复方苦参注射液联合GP方案治疗的有效性及安全性[J].中华中医药学刊,2016,34(4):969-971.
[5]Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors:European Organization for Research and Treatmentof Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
[6]史立波,李卫东,陈信.复方苦参注射液在晚期乳腺癌姑息治疗中的疗效观察[J].中西医结合研究,2015,7(2):60-62.
[7]宋希朋.乳腺癌术后常规化疗辅以中药治疗对患者远期转移复发率及生活质量的影响[J].现代中西医结合杂志,2016,25(33):3670-3672,3715.
[8]李杰宝,张家衡.复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效及其对外周血T细胞亚群的影响研究[J].中国医院药学杂志,2015,35(21):1945-1949.
[9]赖明华.复方苦参注射液对乳腺癌模型大鼠的改善作用[J].中国临床药理学杂志,2017,33(3):244-247.
[10]刘杰,邹剑铭,赵志正,等.复方苦参注射液治疗恶性肿瘤的临床研究现状[J].中国肿瘤临床与康复,2015,22(10):1278-1280.
[11]钱小英,卓曼云,林海锋,等.三阴乳腺癌应用复方苦参注射液联合铂类+吉西他滨化疗的临床观察[J].实用癌症杂志,2017,32(2):305-307,316.
[12]常培江.复方苦参注射液治疗恶性肿瘤癌性疼痛的临床效果评估[J].中国医药指南,2016,14(15):205-206.
[13]唐海峰,朱素楠.苦参碱联合胸腺肽对慢性乙型肝炎患者血清Foxo3a、INF-α、HBV-DNA水平及T细胞亚群的影响[J].海南医学,2017,28(7):1055-1058.
[14]燕忠生,冯石芳,张盼,等.复方苦参注射液联合肝动脉灌注化疗栓塞术治疗原发性肝癌的系统评价[J].中华中医药学刊,2013,31(5):1193-1195.
[15]车瑛琦,武辉宇.复方苦参注射液治疗恶性肿瘤癌性疼痛的临床效果评估[J].中国现代药物应用,2016,10(15):123-124.
[16]苏瑞,李玲,徐宏彬.复方苦参注射液对胃肠道恶性肿瘤辅助治疗的临床观察[J].中国医院药学杂志,2015,35(4):322-325.
[2]李立业.复方苦参注射液联合紫杉醇加阿霉素治疗中晚期乳腺癌临床观察[J].新中医,2016,48(1):158-159.
[3]郭太伟,孙宝刚.复方苦参注射液联合雷替曲塞和奥沙利铂治疗晚期结肠癌的价值探讨[J].中国医药指南,2017,15(30):212-213.
[4]陈晟.晚期非小细胞肺癌应用复方苦参注射液联合GP方案治疗的有效性及安全性[J].中华中医药学刊,2016,34(4):969-971.
[5]Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors:European Organization for Research and Treatmentof Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
[6]史立波,李卫东,陈信.复方苦参注射液在晚期乳腺癌姑息治疗中的疗效观察[J].中西医结合研究,2015,7(2):60-62.
[7]宋希朋.乳腺癌术后常规化疗辅以中药治疗对患者远期转移复发率及生活质量的影响[J].现代中西医结合杂志,2016,25(33):3670-3672,3715.
[8]李杰宝,张家衡.复方苦参注射液治疗乳腺癌术后化疗患者的临床疗效及其对外周血T细胞亚群的影响研究[J].中国医院药学杂志,2015,35(21):1945-1949.
[9]赖明华.复方苦参注射液对乳腺癌模型大鼠的改善作用[J].中国临床药理学杂志,2017,33(3):244-247.
[10]刘杰,邹剑铭,赵志正,等.复方苦参注射液治疗恶性肿瘤的临床研究现状[J].中国肿瘤临床与康复,2015,22(10):1278-1280.
[11]钱小英,卓曼云,林海锋,等.三阴乳腺癌应用复方苦参注射液联合铂类+吉西他滨化疗的临床观察[J].实用癌症杂志,2017,32(2):305-307,316.
[12]常培江.复方苦参注射液治疗恶性肿瘤癌性疼痛的临床效果评估[J].中国医药指南,2016,14(15):205-206.
[13]唐海峰,朱素楠.苦参碱联合胸腺肽对慢性乙型肝炎患者血清Foxo3a、INF-α、HBV-DNA水平及T细胞亚群的影响[J].海南医学,2017,28(7):1055-1058.
[14]燕忠生,冯石芳,张盼,等.复方苦参注射液联合肝动脉灌注化疗栓塞术治疗原发性肝癌的系统评价[J].中华中医药学刊,2013,31(5):1193-1195.
[15]车瑛琦,武辉宇.复方苦参注射液治疗恶性肿瘤癌性疼痛的临床效果评估[J].中国现代药物应用,2016,10(15):123-124.
[16]苏瑞,李玲,徐宏彬.复方苦参注射液对胃肠道恶性肿瘤辅助治疗的临床观察[J].中国医院药学杂志,2015,35(4):322-325.